Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Chronic Disease
Description
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). MeSH
Hierarchy View
Subtype Terms (27)
Candidiasis, Chronic Mucocutaneous
1 approved drug
Chemical and Drug Induced Liver Injury, Chronic
1 approved drug
Chronic Exertional Compartment Syndrome
2 approved drugs
Chronic Kidney Disease-Mineral and Bone Disorder
115 drugs (69 approved, 46 experimental)
Chronic Limb-Threatening Ischemia
69 drugs (25 approved, 44 experimental)
Chronic Periodontitis
78 drugs (33 approved, 45 experimental)
Chronic Urticaria
39 drugs (22 approved, 17 experimental)
Fatigue Syndrome, Chronic
58 drugs (36 approved, 22 experimental)
Granulomatous Disease, Chronic
39 drugs (26 approved, 13 experimental)
Hematoma, Subdural, Chronic
16 drugs (15 approved, 1 experimental)
Hepatitis, Chronic
21 drugs (13 approved, 8 experimental)
Leukemia, Lymphocytic, Chronic, B-Cell
561 drugs (210 approved, 351 experimental)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
245 drugs (127 approved, 118 experimental)
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
128 drugs (99 approved, 29 experimental)
Leukemia, Myelomonocytic, Chronic
199 drugs (113 approved, 86 experimental)
Leukemia, Neutrophilic, Chronic
34 drugs (29 approved, 5 experimental)
Multiple Sclerosis, Chronic Progressive
61 drugs (31 approved, 30 experimental)
Ophthalmoplegia, Chronic Progressive External
1 approved drug
Pancreatitis, Chronic
32 drugs (18 approved, 14 experimental)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
29 drugs (20 approved, 9 experimental)
Pulmonary Disease, Chronic Obstructive
443 drugs (195 approved, 248 experimental)
Renal Insufficiency, Chronic
390 drugs (213 approved, 177 experimental)
Wasting Disease, Chronic
9 drugs (2 approved, 7 experimental)
Phase 1 Indicated Drugs (4)
Other Experimental Indicated Drugs (19)
Organization Involved with Phase 4 Indications (31)
Organization Involved with Phase 3 Indications (35)
Organization Involved with Phase 2 Indications (34)
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (16)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
